<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:23:10 -0700</creation_date>
  <update_date>2013-05-27 11:38:38 -0600</update_date>
  <accession>HMDBP04363</accession>
  <secondary_accessions>
    <accession>9953</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>TS</synonym>
    <synonym>TSase</synonym>
  </synonyms>
  <gene_name>TYMS</gene_name>
  <general_function>Involved in thymidylate synthase activity</general_function>
  <specific_function>Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
</specific_function>
  <pathways>
    <pathway>
      <name>Pyrimidine Metabolism</name>
      <smpdb_id>SMP00046</smpdb_id>
      <kegg_map_id>map00240</kegg_map_id>
    </pathway>
    <pathway>
      <name>Folate Metabolism</name>
      <smpdb_id>SMP00053</smpdb_id>
      <kegg_map_id>map00670</kegg_map_id>
    </pathway>
    <pathway>
      <name>dTTP biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id/>
    </pathway>
    <pathway>
      <name>Pyrimidine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00240</kegg_map_id>
    </pathway>
    <pathway>
      <name>One carbon pool by folate</name>
      <smpdb_id/>
      <kegg_map_id>map00670</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB14438</accession>
      <name>Raltitrexed</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14467</accession>
      <name>Floxuridine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14576</accession>
      <name>Trifluridine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14583</accession>
      <name>Trimethoprim</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14584</accession>
      <name>Gemcitabine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14684</accession>
      <name>Fluorouracil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14703</accession>
      <name>Methotrexate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14780</accession>
      <name>Pemetrexed</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01562</accession>
      <name>N5-Formyl-THF</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15233</accession>
      <name>Capecitabine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01533</accession>
      <name>5,10-Methylene-THF</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01409</accession>
      <name>dUMP</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01056</accession>
      <name>Dihydrofolic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01227</accession>
      <name>5-Thymidylic acid</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity, transferring one-carbon groups</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>methyltransferase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>5,10-methylenetetrahydrofolate-dependent methyltransferase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>thymidylate synthase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nitrogen compound metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular nitrogen compound metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleobase, nucleoside, nucleotide and nucleic acid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleobase, nucleoside and nucleotide metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleoside phosphate metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>nucleotide metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>pyrimidine nucleotide metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>pyrimidine nucleotide biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>pyrimidine nucleoside monophosphate biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>pyrimidine deoxyribonucleoside monophosphate biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>dtmp biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>mitochondrial inner membrane</description>
      <go_id>GO:0005743</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>mitochondrial matrix</description>
      <go_id>GO:0005759</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>nucleoplasm</description>
      <go_id>GO:0005654</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>cofactor binding</description>
      <go_id>GO:0048037</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>folic acid binding</description>
      <go_id>GO:0005542</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>nucleotide binding</description>
      <go_id>GO:0000166</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>thymidylate synthase activity</description>
      <go_id>GO:0004799</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>aging</description>
      <go_id>GO:0007568</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cartilage development</description>
      <go_id>GO:0051216</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>deoxyribonucleoside monophosphate biosynthetic process</description>
      <go_id>GO:0009157</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>developmental growth</description>
      <go_id>GO:0048589</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>DNA repair</description>
      <go_id>GO:0006281</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>DNA replication</description>
      <go_id>GO:0006260</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>dTMP biosynthetic process</description>
      <go_id>GO:0006231</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>dTTP biosynthetic process</description>
      <go_id>GO:0006235</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>dUMP metabolic process</description>
      <go_id>GO:0046078</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>immortalization of host cell by virus</description>
      <go_id>GO:0019088</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>intestinal epithelial cell maturation</description>
      <go_id>GO:0060574</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>organ regeneration</description>
      <go_id>GO:0031100</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>phosphatidylinositol-mediated signaling</description>
      <go_id>GO:0048015</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>pyrimidine nucleobase metabolic process</description>
      <go_id>GO:0006206</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>pyrimidine nucleoside biosynthetic process</description>
      <go_id>GO:0046134</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of transcription involved in G1/S phase of mitotic cell cycle</description>
      <go_id>GO:0000083</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to drug</description>
      <go_id>GO:0042493</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to glucocorticoid stimulus</description>
      <go_id>GO:0051384</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to organophosphorus</description>
      <go_id>GO:0046683</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>18</chromosome_location>
    <locus>18p11.32</locus>
    <gene_sequence>&gt;942 bp
ATGCCTGTGGCCGGCTCGGAGCTGCCGCGCCGGCCCTTGCCCCCCGCCGCACAGGAGCGG
GACGCCGAGCCGCGTCCGCCGCACGGGGAGCTGCAGTACCTGGGGCAGATCCAACACATC
CTCCGCTGCGGCGTCAGGAAGGACGACCGCACGGGCACCGGCACCCTGTCGGTATTCGGC
ATGCAGGCGCGCTACAGCCTGAGAGATGAATTCCCTCTGCTGACAACCAAACGTGTGTTC
TGGAAGGGTGTTTTGGAGGAGTTGCTGTGGTTTATCAAGGGATCCACAAATGCTAAAGAG
CTGTCTTCCAAGGGAGTGAAAATCTGGGATGCCAATGGATCCCGAGACTTTTTGGACAGC
CTGGGATTCTCCACCAGAGAAGAAGGGGACTTGGGCCCAGTTTATGGCTTCCAGTGGAGG
CATTTTGGGGCAGAATACAGAGATATGGAATCAGATTATTCAGGACAGGGAGTTGACCAA
CTGCAAAGAGTGATTGACACCATCAAAACCAACCCTGACGACAGAAGAATCATCATGTGC
GCTTGGAATCCAAGAGATCTTCCTCTGATGGCGCTGCCTCCATGCCATGCCCTCTGCCAG
TTCTATGTGGTGAACAGTGAGCTGTCCTGCCAGCTGTACCAGAGATCGGGAGACATGGGC
CTCGGTGTGCCTTTCAACATCGCCAGCTACGCCCTGCTCACGTACATGATTGCGCACATC
ACGGGCCTGAAGCCAGGTGACTTTATACACACTTTGGGAGATGCACATATTTACCTGAAT
CACATCGAGCCACTGAAAATTCAGCTTCAGCGAGAACCCAGACCTTTCCCAAAGCTCAGG
ATTCTTCGAAAAGTTGAGAAAATTGATGACTTCAAAGCTGAAGACTTTCAGATTGAAGGG
TACAATCCGCATCCAACTATTAAAATGGAAATGGCTGTTTAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>313</residue_number>
    <molecular_weight>35715.65</molecular_weight>
    <theoretical_pi>6.998</theoretical_pi>
    <pfams>
      <pfam>
        <name>Thymidylat_synt</name>
        <pfam_id>PF00303</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Thymidylate synthase
MPVAGSELPRRPLPPAAQERDAEPRPPHGELQYLGQIQHILRCGVRKDDRTGTGTLSVFG
MQARYSLRDEFPLLTTKRVFWKGVLEELLWFIKGSTNAKELSSKGVKIWDANGSRDFLDS
LGFSTREEGDLGPVYGFQWRHFGAEYRDMESDYSGQGVDQLQRVIDTIKTNPDDRRIIMC
AWNPRDLPLMALPPCHALCQFYVVNSELSCQLYQRSGDMGLGVPFNIASYALLTYMIAHI
TGLKPGDFIHTLGDAHIYLNHIEPLKIQLQREPRPFPKLRILRKVEKIDDFKAEDFQIEG
YNPHPTIKMEMAV</protein_sequence>
  </protein_properties>
  <genbank_protein_id>37479</genbank_protein_id>
  <uniprot_id>P04818</uniprot_id>
  <uniprot_name>TYSY_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1HVY</pdb_id>
    <pdb_id>1HW3</pdb_id>
    <pdb_id>1HW4</pdb_id>
    <pdb_id>1HZW</pdb_id>
    <pdb_id>1I00</pdb_id>
    <pdb_id>1JU6</pdb_id>
    <pdb_id>1JUJ</pdb_id>
    <pdb_id>1YPV</pdb_id>
    <pdb_id>2ONB</pdb_id>
    <pdb_id>2RD8</pdb_id>
    <pdb_id>2RDA</pdb_id>
    <pdb_id>3EAW</pdb_id>
    <pdb_id>3EBU</pdb_id>
    <pdb_id>3ED7</pdb_id>
    <pdb_id>3EDW</pdb_id>
    <pdb_id>3EF9</pdb_id>
    <pdb_id>3EGY</pdb_id>
    <pdb_id>3EHI</pdb_id>
    <pdb_id>3EJL</pdb_id>
    <pdb_id>3GG5</pdb_id>
    <pdb_id>3GH0</pdb_id>
    <pdb_id>3GH2</pdb_id>
    <pdb_id>3H9K</pdb_id>
    <pdb_id>3HB8</pdb_id>
    <pdb_id>3N5E</pdb_id>
    <pdb_id>3N5G</pdb_id>
    <pdb_id>3OB7</pdb_id>
    <pdb_id>4E28</pdb_id>
    <pdb_id>4GYH</pdb_id>
    <pdb_id>4H1I</pdb_id>
  </pdb_ids>
  <genbank_gene_id>X02308</genbank_gene_id>
  <genecard_id>TYMS</genecard_id>
  <geneatlas_id>TYMS</geneatlas_id>
  <hgnc_id>HGNC:12441</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Takeishi K, Kaneda S, Ayusawa D, Shimizu K, Gotoh O, Seno T: Nucleotide sequence of a functional cDNA for human thymidylate synthase.  Nucleic Acids Res. 1985 Mar 25;13(6):2035-43.</reference_text>
      <pubmed_id>2987839</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kaneda S, Nalbantoglu J, Takeishi K, Shimizu K, Gotoh O, Seno T, Ayusawa D: Structural and functional analysis of the human thymidylate synthase gene.  J Biol Chem. 1990 Nov 25;265(33):20277-84.</reference_text>
      <pubmed_id>2243092</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Takeishi K, Kaneda S, Ayusawa D, Shimizu K, Gotoh O, Seno T: Human thymidylate synthase gene: isolation of phage clones which cover a functionally active gene and structural analysis of the region upstream from the translation initiation codon. J Biochem (Tokyo). 1989 Oct;106(4):575-83.</reference_text>
      <pubmed_id>2532645</pubmed_id>
    </reference>
    <reference>
      <reference_text>Shimizu K, Ayusawa D, Takeishi K, Seno T: Purification and NH2-terminal amino acid sequence of human thymidylate synthase in an overproducing transformant of mouse FM3A cells. J Biochem (Tokyo). 1985 Mar;97(3):845-50.</reference_text>
      <pubmed_id>3839505</pubmed_id>
    </reference>
    <reference>
      <reference_text>Davisson VJ, Sirawaraporn W, Santi DV: Expression of human thymidylate synthase in Escherichia coli.  J Biol Chem. 1989 Jun 5;264(16):9145-8.</reference_text>
      <pubmed_id>2656695</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mayya V, Lundgren DH, Hwang SI, Rezaul K, Wu L, Eng JK, Rodionov V, Han DK: Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal. 2009 Aug 18;2(84):ra46.</reference_text>
      <pubmed_id>19690332</pubmed_id>
    </reference>
    <reference>
      <reference_text>Schiffer CA, Clifton IJ, Davisson VJ, Santi DV, Stroud RM: Crystal structure of human thymidylate synthase: a structural mechanism for guiding substrates into the active site. Biochemistry. 1995 Dec 19;34(50):16279-87.</reference_text>
      <pubmed_id>8845352</pubmed_id>
    </reference>
    <reference>
      <reference_text>Phan J, Koli S, Minor W, Dunlap RB, Berger SH, Lebioda L: Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug. Biochemistry. 2001 Feb 20;40(7):1897-902.</reference_text>
      <pubmed_id>11329255</pubmed_id>
    </reference>
    <reference>
      <reference_text>Phan J, Steadman DJ, Koli S, Ding WC, Minor W, Dunlap RB, Berger SH, Lebioda L: Structure of human thymidylate synthase suggests advantages of chemotherapy with noncompetitive inhibitors. J Biol Chem. 2001 Apr 27;276(17):14170-7. Epub 2001 Jan 24.</reference_text>
      <pubmed_id>11278511</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Raltitrexed</name>
        <accession>HMDB14438</accession>
      </metabolite>
      <reference>
        <reference_text>Yin MB, Guo B, Panadero A, Frank C, Wrzosek C, Slocum HK, Rustum YM: Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex. Exp Cell Res. 1999 Feb 25;247(1):189-99.</reference_text>
        <pubmed_id>10047461</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raltitrexed</name>
        <accession>HMDB14438</accession>
      </metabolite>
      <reference>
        <reference_text>Cao S, McGuire JJ, Rustum YM: Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine. Clin Cancer Res. 1999 Jul;5(7):1925-34.</reference_text>
        <pubmed_id>10430100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raltitrexed</name>
        <accession>HMDB14438</accession>
      </metabolite>
      <reference>
        <reference_text>Ferguson PJ, Collins O, Dean NM, DeMoor J, Li CS, Vincent MD, Koropatnick J: Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86.</reference_text>
        <pubmed_id>10482907</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raltitrexed</name>
        <accession>HMDB14438</accession>
      </metabolite>
      <reference>
        <reference_text>Orlandi L, Bearzatto A, Abolafio G, De Marco C, Daidone MG, Zaffaroni N: Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex. Br J Cancer. 1999 Sep;81(2):252-60.</reference_text>
        <pubmed_id>10496350</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raltitrexed</name>
        <accession>HMDB14438</accession>
      </metabolite>
      <reference>
        <reference_text>Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG, Allegra CJ: A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors. Clin Cancer Res. 1999 Sep;5(9):2381-91.</reference_text>
        <pubmed_id>10499608</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raltitrexed</name>
        <accession>HMDB14438</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raltitrexed</name>
        <accession>HMDB14438</accession>
      </metabolite>
      <reference>
        <reference_text>Yang Z, Waldman AS, Wyatt MD: DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96. Epub 2008 Aug 19.</reference_text>
        <pubmed_id>18773878</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raltitrexed</name>
        <accession>HMDB14438</accession>
      </metabolite>
      <reference>
        <reference_text>Chen VJ, Bewley JR, Andis SL, Schultz RM, Iversen PW, Shih C, Mendelsohn LG, Seitz DE, Tonkinson JL: Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Semin Oncol. 1999 Apr;26(2 Suppl 6):48-54.</reference_text>
        <pubmed_id>10598555</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raltitrexed</name>
        <accession>HMDB14438</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Floxuridine</name>
        <accession>HMDB14467</accession>
      </metabolite>
      <reference>
        <reference_text>Ferguson PJ, Collins O, Dean NM, DeMoor J, Li CS, Vincent MD, Koropatnick J: Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86.</reference_text>
        <pubmed_id>10482907</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Floxuridine</name>
        <accession>HMDB14467</accession>
      </metabolite>
      <reference>
        <reference_text>Kubota T: [Theoretical basis for low-dose CDDP/5-FU therapy].  Gan To Kagaku Ryoho. 1999 Oct;26(11):1536-41.</reference_text>
        <pubmed_id>10553409</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Floxuridine</name>
        <accession>HMDB14467</accession>
      </metabolite>
      <reference>
        <reference_text>Kuwa K, Sakamoto S, Sassa S, Yoshimura S, Maemura M, Nakayama T: Effects of long-term administration of UFT plus leucovorin on colorectal tumors induced with 1,2-dimethylhydrazine in rats. Anticancer Res. 1999 Nov-Dec;19(6B):5139-42.</reference_text>
        <pubmed_id>10697523</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Floxuridine</name>
        <accession>HMDB14467</accession>
      </metabolite>
      <reference>
        <reference_text>Kuwa K, Sakamoto S, Mitamura T, Kudo H, Suzuki S, Fukushima M: Effects of a low dose leucovorin with 5-fluorouracil derivative on colorectal tumors induced with 1,2-dimethylhydrazine in rats. Anticancer Res. 1999 Nov-Dec;19(6B):5143-8.</reference_text>
        <pubmed_id>10697524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Floxuridine</name>
        <accession>HMDB14467</accession>
      </metabolite>
      <reference>
        <reference_text>Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N, Fukushima M: Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol. 2000 Aug;17(2):277-83.</reference_text>
        <pubmed_id>10891536</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Floxuridine</name>
        <accession>HMDB14467</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>De Clercq E: Antiviral drugs in current clinical use.  J Clin Virol. 2004 Jun;30(2):115-33.</reference_text>
        <pubmed_id>15125867</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Bijnsdorp IV, Kruyt FA, Fukushima M, Smid K, Gokoel S, Peters GJ: Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines. Cancer Sci. 2010 Feb;101(2):440-7. Epub 2009 Sep 29.</reference_text>
        <pubmed_id>19886911</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Bijnsdorp IV, Peters GJ, Temmink OH, Fukushima M, Kruyt FA: Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int J Cancer. 2010 May 15;126(10):2457-68.</reference_text>
        <pubmed_id>19816940</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Bijnsdorp IV, Kruyt FA, Fukushima M, Peters GJ: Trifluorothymidine induces cell death independently of p53.  Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703.</reference_text>
        <pubmed_id>18600528</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Madeira VM, Antunes-Madeira MC: Chemical composition of sarcolemma isolated from rabbit skeletal muscle.  Biochim Biophys Acta. 1973 Mar 16;298(2):230-8.</reference_text>
        <pubmed_id>4719131</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Temmink OH, Hoogeland MF, Fukushima M, Peters GJ: Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. Cancer Chemother Pharmacol. 2006 Jan;57(2):171-9. Epub 2005 Jul 12.</reference_text>
        <pubmed_id>16010590</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Oberg B, Johansson NG: The relative merits and drawbacks of new nucleoside analogues with clinical potential. J Antimicrob Chemother. 1984 Aug;14 Suppl A:5-26.</reference_text>
        <pubmed_id>6436227</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Temmink OH, Comijn EM, Fukushima M, Peters GJ: Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1491-4.</reference_text>
        <pubmed_id>15571283</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Shintani M, Urano M, Takakuwa Y, Kuroda M, Kamoshida S: Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer. Oncol Rep. 2010 May;23(5):1345-50.</reference_text>
        <pubmed_id>20372850</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Emura T, Nakagawa F, Fujioka A, Ohshimo H, Kitazato K: Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model. Oncol Rep. 2004 Feb;11(2):381-7.</reference_text>
        <pubmed_id>14719072</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL: Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct;26(8):794-9.</reference_text>
        <pubmed_id>18798063</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM: Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer. 2006 Sep 15;107(6):1383-90.</reference_text>
        <pubmed_id>16902987</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Temmink OH, Prins HJ, van Gelderop E, Peters GJ: The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. Br J Cancer. 2007 Jan 15;96(1):61-6. Epub 2006 Dec 19.</reference_text>
        <pubmed_id>17179993</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluridine</name>
        <accession>HMDB14576</accession>
      </metabolite>
      <reference>
        <reference_text>Bassler R, Buchwald W: [Experimental inflammation and fibrosis of the lung framework caused by ionizing rays. Light and electron microscopic studies]. Fortschr Geb Rontgenstr Nuklearmed. 1966 Feb;104(2):192-206.</reference_text>
        <pubmed_id>6010427</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Gamarro F, Yu PL, Zhao J, Edman U, Greene PJ, Santi D: Trypanosoma brucei dihydrofolate reductase-thymidylate synthase: gene isolation and expression and characterization of the enzyme. Mol Biochem Parasitol. 1995 Jun;72(1-2):11-22.</reference_text>
        <pubmed_id>8538681</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Rosowsky A, Papoulis AT, Forsch RA, Queener SF: Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim. J Med Chem. 1999 Mar 25;42(6):1007-17.</reference_text>
        <pubmed_id>10090784</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Reche P, Arrebola R, Santi DV, Gonzalez-Pacanowska D, Ruiz-Perez LM: Expression and characterization of the Trypanosoma cruzi dihydrofolate reductase domain. Mol Biochem Parasitol. 1996 Feb-Mar;76(1-2):175-85.</reference_text>
        <pubmed_id>8920005</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Oefner C, Parisi S, Schulz H, Lociuro S, Dale GE: Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus. Acta Crystallogr D Biol Crystallogr. 2009 Aug;65(Pt 8):751-7. Epub 2009 Jul 10.</reference_text>
        <pubmed_id>19622858</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gemcitabine</name>
        <accession>HMDB14584</accession>
      </metabolite>
      <reference>
        <reference_text>Rosell R, Taron M, Sanchez JM, Moran T, Reguart N, Besse B, Isla D, Massuti B, Alberola V, Sanchez JJ: The promise of pharmacogenomics: gemcitabine and pemetrexed.  Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):70-6.</reference_text>
        <pubmed_id>15655942</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gemcitabine</name>
        <accession>HMDB14584</accession>
      </metabolite>
      <reference>
        <reference_text>Huang CL, Yokomise H, Fukushima M, Kinoshita M: Tailor-made chemotherapy for non-small cell lung cancer patients.  Future Oncol. 2006 Apr;2(2):289-99.</reference_text>
        <pubmed_id>16563096</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gemcitabine</name>
        <accession>HMDB14584</accession>
      </metabolite>
      <reference>
        <reference_text>Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8. Epub 2005 Mar 28.</reference_text>
        <pubmed_id>15795320</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gemcitabine</name>
        <accession>HMDB14584</accession>
      </metabolite>
      <reference>
        <reference_text>Zhao XD, Zhang Y: [Routine chemotherapeutic drug treatment effectiveness predictive molecules and chemotherapeutic drug selection]. Ai Zheng. 2006 Dec;25(12):1577-80.</reference_text>
        <pubmed_id>17166391</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gemcitabine</name>
        <accession>HMDB14584</accession>
      </metabolite>
      <reference>
        <reference_text>Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R: Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer.  Mol Cancer Ther. 2006 Jun;5(6):1387-95.</reference_text>
        <pubmed_id>16818496</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gemcitabine</name>
        <accession>HMDB14584</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluorouracil</name>
        <accession>HMDB14684</accession>
      </metabolite>
      <reference>
        <reference_text>Formentini A, Sander S, Denzer S, Straeter J, Henne-Bruns D, Kornmann M: Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? Int J Colorectal Dis. 2007 Jan;22(1):49-55. Epub 2006 Mar 15.</reference_text>
        <pubmed_id>16538493</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluorouracil</name>
        <accession>HMDB14684</accession>
      </metabolite>
      <reference>
        <reference_text>Huang CL, Yokomise H, Fukushima M, Kinoshita M: Tailor-made chemotherapy for non-small cell lung cancer patients.  Future Oncol. 2006 Apr;2(2):289-99.</reference_text>
        <pubmed_id>16563096</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluorouracil</name>
        <accession>HMDB14684</accession>
      </metabolite>
      <reference>
        <reference_text>Fernandez-Contreras ME, Sanchez-Prudencio S, Sanchez-Hernandez JJ, Garcia de Paredes ML, Gisbert JP, Roda-Navarro P, Gamallo C: Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. Int J Oncol. 2006 May;28(5):1303-10.</reference_text>
        <pubmed_id>16596248</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluorouracil</name>
        <accession>HMDB14684</accession>
      </metabolite>
      <reference>
        <reference_text>Garcia V, Garcia JM, Pena C, Silva J, Dominguez G, Hurtado A, Alonso I, Rodriguez R, Provencio M, Bonilla F: Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2095-100.</reference_text>
        <pubmed_id>16609021</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluorouracil</name>
        <accession>HMDB14684</accession>
      </metabolite>
      <reference>
        <reference_text>Ploylearmsaeng SA, Fuhr U, Jetter A: How may anticancer chemotherapy with fluorouracil be individualised?  Clin Pharmacokinet. 2006;45(6):567-92.</reference_text>
        <pubmed_id>16719540</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluorouracil</name>
        <accession>HMDB14684</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluorouracil</name>
        <accession>HMDB14684</accession>
      </metabolite>
      <reference>
        <reference_text>Rustum YM: Thymidylate synthase: a critical target in cancer therapy?  Front Biosci. 2004 Sep 1;9:2467-73.</reference_text>
        <pubmed_id>15353299</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluorouracil</name>
        <accession>HMDB14684</accession>
      </metabolite>
      <reference>
        <reference_text>Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S: 5-Fluorouracil pharmacogenomics: still rocking after all these years?  Pharmacogenomics. 2011 Feb;12(2):251-65.</reference_text>
        <pubmed_id>21332317</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate.  Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24.</reference_text>
        <pubmed_id>17586865</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Adjei AA: Gemcitabine and Pemetrexed disodium in treating breast cancer.  Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7.</reference_text>
        <pubmed_id>11252887</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73.</reference_text>
        <pubmed_id>11524555</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001 Sep 1;85(5):649-55.</reference_text>
        <pubmed_id>11531245</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Adjei AA: Gemcitabine and pemetrexed disodium combinations in vitro and in vivo.  Lung Cancer. 2001 Dec;34 Suppl 4:S103-5.</reference_text>
        <pubmed_id>11742712</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Norman P: Pemetrexed disodium (Eli Lilly).  Curr Opin Investig Drugs. 2001 Nov;2(11):1611-22.</reference_text>
        <pubmed_id>11763166</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Schultz RM, Dempsey JA: Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res. 2001 Sep-Oct;21(5):3209-14.</reference_text>
        <pubmed_id>11848474</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Adjei AA: Pemetrexed in the treatment of selected solid tumors.  Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3.</reference_text>
        <pubmed_id>12023793</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Molina JR, Adjei AA: The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.  Clin Lung Cancer. 2003 Jul;5(1):21-7.</reference_text>
        <pubmed_id>14596699</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8. Epub 2005 Mar 28.</reference_text>
        <pubmed_id>15795320</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemetrexed</name>
        <accession>HMDB14780</accession>
      </metabolite>
      <reference>
        <reference_text>Kindler HL: Pemetrexed in pancreatic cancer.  Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53.</reference_text>
        <pubmed_id>12571811</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N5-Formyl-THF</name>
        <accession>HMDB01562</accession>
      </metabolite>
      <reference>
        <reference_text>Aschele C, Debernardis D, Bandelloni R, Cascinu S, Catalano V, Giordani P, Barni S, Turci D, Drudi G, Lonardi S, Gallo L, Maley F, Monfardini S: Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. Ann Oncol. 2002 Dec;13(12):1882-92.</reference_text>
        <pubmed_id>12453856</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N5-Formyl-THF</name>
        <accession>HMDB01562</accession>
      </metabolite>
      <reference>
        <reference_text>Zhu AX, Puchalski TA, Stanton VP Jr, Ryan DP, Clark JW, Nesbitt S, Charlat O, Kelly P, Kreconus E, Chabner BA, Supko JG: Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. Clin Colorectal Cancer. 2004 Feb;3(4):225-34.</reference_text>
        <pubmed_id>15025795</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N5-Formyl-THF</name>
        <accession>HMDB01562</accession>
      </metabolite>
      <reference>
        <reference_text>Smorenburg CH, Peters GJ, van Groeningen CJ, Noordhuis P, Smid K, van Riel AM, Dercksen W, Pinedo HM, Giaccone G: Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol. 2006 Jan;17(1):35-42. Epub 2005 Oct 26.</reference_text>
        <pubmed_id>16251201</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N5-Formyl-THF</name>
        <accession>HMDB01562</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Patel A, Pluim T, Helms A, Bauer A, Tuttle RM, Francis GL: Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults. Cancer Chemother Pharmacol. 2004 May;53(5):409-14.</reference_text>
        <pubmed_id>15132128</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Eliason JF, Megyeri A: Potential for predicting toxicity and response of fluoropyrimidines in patients.  Curr Drug Targets. 2004 May;5(4):383-8.</reference_text>
        <pubmed_id>15134221</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.</reference_text>
        <pubmed_id>15709193</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Li KM, Rivory LP, Clarke SJ: Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jun 5;820(1):121-30.       Epub 2005 Apr 19.</reference_text>
        <pubmed_id>15866500</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Fischel JL, Ciccolini J, Formento P, Ferrero JM, Milano G: Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine. Anticancer Drugs. 2006 Aug;17(7):807-13.</reference_text>
        <pubmed_id>16926630</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Capecitabine</name>
        <accession>HMDB15233</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
